
News|Podcasts|August 21, 2023
Pharmacy Focus: Oncology Edition - PARP Inhibitors Are Changing the Game in Prostate Cancer
This month, we spoke with Cassia Griswold, PharmD, a clinical oncology pharmacist at Mayo Clinic Arizona.
Advertisement
This month, we spoke with Cassia Griswold, PharmD, a clinical oncology pharmacist at Mayo Clinic Arizona. Griswold discussed the latest updates from ASCO in PARP inhibitors for prostate cancer, as well as what's on the horizon in this quickly-evolving treatment space.
Interested in learning more? Check out this related content:
FDA Approves New Combination Therapy for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer Image-Guided Adaptive Radiation Treatments May Reduce Short-Term Adverse Effects in Patients With Prostate Cancer Compared to Non-Adaptive Treatments Enzalutamide Combination, Monotherapy Reduced the Risk of Metastasis or Death in High-Risk Patients With Prostate Cancer
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
OpEd: The Drug Enforcement Administration Needs a Chief Pharmacy Officer. Here’s Why
2
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
3
Pharmacy Policy Updates for October 2025
4
Inhaled Insulin Demonstrates Comparable Safety, Lung Function, and Efficacy to Injectable Insulin in Type 1 Diabetes
5